Erschienen in:
01.04.2017 | Cardio-Oncology (SA Francis, Section Editor)
Cardio-oncology: the Nuclear Option
verfasst von:
Jorge A. Alvarez, Raymond R. Russell
Erschienen in:
Current Cardiology Reports
|
Ausgabe 4/2017
Einloggen, um Zugang zu erhalten
Abstract
Purpose of Review
Cardio-oncology focuses increased effort to decrease cancer treatment-related cardiotoxicity while continuing to improve outcomes. We sought to synthesize the latest in nuclear cardiology as it pertains to the assessment of left ventricular function in preventative guidelines and comparison to other modalities, novel molecular markers of pre-clinical cardiotoxicity, and its role in cardiac amyloid diagnosis.
Recent Findings
Planar ERNA (equilibrium radionuclide angiocardiography) provides a reliable and proven means of monitoring and preventing anthracycline cardiotoxicity, and SPECT ERNA using solid-state gamma cameras may provide reproducible assessments of left ventricular function with reduced radiation exposure. While certain chemotherapeutics have vascular side effects, the use of stress perfusion imaging has still not been adequately studied for routine use. Similarly, markers of apoptosis, inflammation, and sympathetic nerve dysfunction are promising, but are still not ready for uniform usage. SPECT tracers can assist in nonbiopsy diagnosis of cardiac amyloid.
Summary
Nuclear cardiology is a significant contributor to the multimodality approach to cardio-oncology.